Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f277ede6cef-trace').style.display = (document.getElementById('cakeErr67f277ede6cef-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f277ede6cef-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f277ede6cef-code').style.display = (document.getElementById('cakeErr67f277ede6cef-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f277ede6cef-context').style.display = (document.getElementById('cakeErr67f277ede6cef-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f277ede6cef-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f277ede6cef-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 22510,
		&#039;title&#039; =&gt; &#039;Clinical trials: Expert panel&amp;#039;s views differ from formula under study-Sushmi Dey&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Confusion over clinical trial compensation norms&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government&#039;s department of health and family welfare, work in the industry&#039;s favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&amp;quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &amp;quot;If they are not given compensation, their family members may not like to enrol them.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&amp;quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the formula under the health ministry&#039;s consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &amp;quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&amp;quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &amp;quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&amp;quot; the report said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;LATERAL SHIFT&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Key suggestions of the Ranjit Roy Chaudhary panel
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Audio-visual recording of the informed consent process be undertaken and the documentation preserved
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Compensation need not be paid for injury or death due to totally-proven unrelated causes
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* IT be used at all steps of a clinical trial to ensure total transparency in the system
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 14 September, 2013, http://www.business-standard.com/article/economy-policy/clinical-trials-expert-panel-s-views-differ-from-formula-under-study-113091400575_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 22660,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 22510,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Clinical trials: Expert panel&amp;#039;s views differ from formula under study-Sushmi Dey&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Clinical Trials,Health,Law and Justice,Human Rights,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard



Confusion over clinical trial compensation norms


Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Confusion over clinical trial compensation norms&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government&#039;s department of health and family welfare, work in the industry&#039;s favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&amp;quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &amp;quot;If they are not given compensation, their family members may not like to enrol them.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&amp;quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the formula under the health ministry&#039;s consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &amp;quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&amp;quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &amp;quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&amp;quot; the report said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;LATERAL SHIFT&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Key suggestions of the Ranjit Roy Chaudhary panel&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Audio-visual recording of the informed consent process be undertaken and the documentation preserved&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Compensation need not be paid for injury or death due to totally-proven unrelated causes&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* IT be used at all steps of a clinical trial to ensure total transparency in the system&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 22510,
	&#039;title&#039; =&gt; &#039;Clinical trials: Expert panel&amp;#039;s views differ from formula under study-Sushmi Dey&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Confusion over clinical trial compensation norms&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government&#039;s department of health and family welfare, work in the industry&#039;s favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&amp;quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &amp;quot;If they are not given compensation, their family members may not like to enrol them.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&amp;quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the formula under the health ministry&#039;s consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &amp;quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&amp;quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &amp;quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&amp;quot; the report said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;LATERAL SHIFT&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Key suggestions of the Ranjit Roy Chaudhary panel
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Audio-visual recording of the informed consent process be undertaken and the documentation preserved
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Compensation need not be paid for injury or death due to totally-proven unrelated causes
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* IT be used at all steps of a clinical trial to ensure total transparency in the system
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 14 September, 2013, http://www.business-standard.com/article/economy-policy/clinical-trials-expert-panel-s-views-differ-from-formula-under-study-113091400575_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 22660,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 22510
$metaTitle = &#039;LATEST NEWS UPDATES | Clinical trials: Expert panel&amp;#039;s views differ from formula under study-Sushmi Dey&#039;
$metaKeywords = &#039;Clinical Trials,Health,Law and Justice,Human Rights,medicines&#039;
$metaDesc = &#039;
-The Business Standard



Confusion over clinical trial compensation norms


Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Confusion over clinical trial compensation norms&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government&#039;s department of health and family welfare, work in the industry&#039;s favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&amp;quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &amp;quot;If they are not given compensation, their family members may not like to enrol them.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&amp;quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the formula under the health ministry&#039;s consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &amp;quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&amp;quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &amp;quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&amp;quot; the report said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;LATERAL SHIFT&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Key suggestions of the Ranjit Roy Chaudhary panel&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Audio-visual recording of the informed consent process be undertaken and the documentation preserved&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Compensation need not be paid for injury or death due to totally-proven unrelated causes&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* IT be used at all steps of a clinical trial to ensure total transparency in the system&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Clinical trials: Expert panel&#039;s views differ from formula under study-Sushmi Dey | Im4change.org</title>
    <meta name="description" content="
-The Business Standard



Confusion over clinical trial compensation norms


Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Clinical trials: Expert panel&#039;s views differ from formula under study-Sushmi Dey</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Business Standard</div><p align="justify"><br /><em>Confusion over clinical trial compensation norms</em></p><p align="justify">Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.</p><p align="justify">The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.</p><p align="justify">This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.</p><p align="justify">The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government's department of health and family welfare, work in the industry's favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.</p><p align="justify">&quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &quot;If they are not given compensation, their family members may not like to enrol them.&quot;</p><p align="justify">However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.</p><p align="justify">&quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).</p><p align="justify">According to the formula under the health ministry's consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.</p><p align="justify">The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.</p><p align="justify">Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&quot; the report said.</p><p align="justify"><strong>LATERAL SHIFT</strong></p><p align="justify">Key suggestions of the Ranjit Roy Chaudhary panel</p><p align="justify">* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees</p><p align="justify">* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee</p><p align="justify">* Audio-visual recording of the informed consent process be undertaken and the documentation preserved</p><p align="justify">* Compensation need not be paid for injury or death due to totally-proven unrelated causes</p><p align="justify">* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs</p><p align="justify">* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation</p><p align="justify">* IT be used at all steps of a clinical trial to ensure total transparency in the system</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f277ede6cef-trace').style.display = (document.getElementById('cakeErr67f277ede6cef-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f277ede6cef-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f277ede6cef-code').style.display = (document.getElementById('cakeErr67f277ede6cef-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f277ede6cef-context').style.display = (document.getElementById('cakeErr67f277ede6cef-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f277ede6cef-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f277ede6cef-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 22510,
		&#039;title&#039; =&gt; &#039;Clinical trials: Expert panel&amp;#039;s views differ from formula under study-Sushmi Dey&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Confusion over clinical trial compensation norms&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government&#039;s department of health and family welfare, work in the industry&#039;s favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&amp;quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &amp;quot;If they are not given compensation, their family members may not like to enrol them.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&amp;quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the formula under the health ministry&#039;s consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &amp;quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&amp;quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &amp;quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&amp;quot; the report said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;LATERAL SHIFT&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Key suggestions of the Ranjit Roy Chaudhary panel
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Audio-visual recording of the informed consent process be undertaken and the documentation preserved
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Compensation need not be paid for injury or death due to totally-proven unrelated causes
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* IT be used at all steps of a clinical trial to ensure total transparency in the system
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 14 September, 2013, http://www.business-standard.com/article/economy-policy/clinical-trials-expert-panel-s-views-differ-from-formula-under-study-113091400575_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 22660,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 22510,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Clinical trials: Expert panel&amp;#039;s views differ from formula under study-Sushmi Dey&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Clinical Trials,Health,Law and Justice,Human Rights,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard



Confusion over clinical trial compensation norms


Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Confusion over clinical trial compensation norms&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government&#039;s department of health and family welfare, work in the industry&#039;s favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&amp;quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &amp;quot;If they are not given compensation, their family members may not like to enrol them.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&amp;quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the formula under the health ministry&#039;s consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &amp;quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&amp;quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &amp;quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&amp;quot; the report said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;LATERAL SHIFT&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Key suggestions of the Ranjit Roy Chaudhary panel&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Audio-visual recording of the informed consent process be undertaken and the documentation preserved&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Compensation need not be paid for injury or death due to totally-proven unrelated causes&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* IT be used at all steps of a clinical trial to ensure total transparency in the system&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 22510,
	&#039;title&#039; =&gt; &#039;Clinical trials: Expert panel&amp;#039;s views differ from formula under study-Sushmi Dey&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Confusion over clinical trial compensation norms&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government&#039;s department of health and family welfare, work in the industry&#039;s favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&amp;quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &amp;quot;If they are not given compensation, their family members may not like to enrol them.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&amp;quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the formula under the health ministry&#039;s consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &amp;quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&amp;quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &amp;quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&amp;quot; the report said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;LATERAL SHIFT&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Key suggestions of the Ranjit Roy Chaudhary panel
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Audio-visual recording of the informed consent process be undertaken and the documentation preserved
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Compensation need not be paid for injury or death due to totally-proven unrelated causes
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* IT be used at all steps of a clinical trial to ensure total transparency in the system
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 14 September, 2013, http://www.business-standard.com/article/economy-policy/clinical-trials-expert-panel-s-views-differ-from-formula-under-study-113091400575_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 22660,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 22510
$metaTitle = &#039;LATEST NEWS UPDATES | Clinical trials: Expert panel&amp;#039;s views differ from formula under study-Sushmi Dey&#039;
$metaKeywords = &#039;Clinical Trials,Health,Law and Justice,Human Rights,medicines&#039;
$metaDesc = &#039;
-The Business Standard



Confusion over clinical trial compensation norms


Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Confusion over clinical trial compensation norms&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government&#039;s department of health and family welfare, work in the industry&#039;s favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&amp;quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &amp;quot;If they are not given compensation, their family members may not like to enrol them.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&amp;quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the formula under the health ministry&#039;s consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &amp;quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&amp;quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &amp;quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&amp;quot; the report said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;LATERAL SHIFT&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Key suggestions of the Ranjit Roy Chaudhary panel&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Audio-visual recording of the informed consent process be undertaken and the documentation preserved&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Compensation need not be paid for injury or death due to totally-proven unrelated causes&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* IT be used at all steps of a clinical trial to ensure total transparency in the system&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Clinical trials: Expert panel&#039;s views differ from formula under study-Sushmi Dey | Im4change.org</title>
    <meta name="description" content="
-The Business Standard



Confusion over clinical trial compensation norms


Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Clinical trials: Expert panel&#039;s views differ from formula under study-Sushmi Dey</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Business Standard</div><p align="justify"><br /><em>Confusion over clinical trial compensation norms</em></p><p align="justify">Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.</p><p align="justify">The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.</p><p align="justify">This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.</p><p align="justify">The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government's department of health and family welfare, work in the industry's favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.</p><p align="justify">&quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &quot;If they are not given compensation, their family members may not like to enrol them.&quot;</p><p align="justify">However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.</p><p align="justify">&quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).</p><p align="justify">According to the formula under the health ministry's consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.</p><p align="justify">The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.</p><p align="justify">Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&quot; the report said.</p><p align="justify"><strong>LATERAL SHIFT</strong></p><p align="justify">Key suggestions of the Ranjit Roy Chaudhary panel</p><p align="justify">* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees</p><p align="justify">* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee</p><p align="justify">* Audio-visual recording of the informed consent process be undertaken and the documentation preserved</p><p align="justify">* Compensation need not be paid for injury or death due to totally-proven unrelated causes</p><p align="justify">* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs</p><p align="justify">* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation</p><p align="justify">* IT be used at all steps of a clinical trial to ensure total transparency in the system</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f277ede6cef-trace').style.display = (document.getElementById('cakeErr67f277ede6cef-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f277ede6cef-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f277ede6cef-code').style.display = (document.getElementById('cakeErr67f277ede6cef-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f277ede6cef-context').style.display = (document.getElementById('cakeErr67f277ede6cef-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f277ede6cef-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f277ede6cef-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 22510,
		&#039;title&#039; =&gt; &#039;Clinical trials: Expert panel&amp;#039;s views differ from formula under study-Sushmi Dey&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Confusion over clinical trial compensation norms&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government&#039;s department of health and family welfare, work in the industry&#039;s favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&amp;quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &amp;quot;If they are not given compensation, their family members may not like to enrol them.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&amp;quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the formula under the health ministry&#039;s consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &amp;quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&amp;quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &amp;quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&amp;quot; the report said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;LATERAL SHIFT&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Key suggestions of the Ranjit Roy Chaudhary panel
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Audio-visual recording of the informed consent process be undertaken and the documentation preserved
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Compensation need not be paid for injury or death due to totally-proven unrelated causes
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* IT be used at all steps of a clinical trial to ensure total transparency in the system
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 14 September, 2013, http://www.business-standard.com/article/economy-policy/clinical-trials-expert-panel-s-views-differ-from-formula-under-study-113091400575_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 22660,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 22510,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Clinical trials: Expert panel&amp;#039;s views differ from formula under study-Sushmi Dey&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Clinical Trials,Health,Law and Justice,Human Rights,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard



Confusion over clinical trial compensation norms


Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Confusion over clinical trial compensation norms&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government&#039;s department of health and family welfare, work in the industry&#039;s favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&amp;quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &amp;quot;If they are not given compensation, their family members may not like to enrol them.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&amp;quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the formula under the health ministry&#039;s consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &amp;quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&amp;quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &amp;quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&amp;quot; the report said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;LATERAL SHIFT&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Key suggestions of the Ranjit Roy Chaudhary panel&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Audio-visual recording of the informed consent process be undertaken and the documentation preserved&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Compensation need not be paid for injury or death due to totally-proven unrelated causes&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* IT be used at all steps of a clinical trial to ensure total transparency in the system&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 22510,
	&#039;title&#039; =&gt; &#039;Clinical trials: Expert panel&amp;#039;s views differ from formula under study-Sushmi Dey&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Confusion over clinical trial compensation norms&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government&#039;s department of health and family welfare, work in the industry&#039;s favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&amp;quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &amp;quot;If they are not given compensation, their family members may not like to enrol them.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&amp;quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the formula under the health ministry&#039;s consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &amp;quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&amp;quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &amp;quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&amp;quot; the report said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;LATERAL SHIFT&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Key suggestions of the Ranjit Roy Chaudhary panel
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Audio-visual recording of the informed consent process be undertaken and the documentation preserved
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Compensation need not be paid for injury or death due to totally-proven unrelated causes
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
* IT be used at all steps of a clinical trial to ensure total transparency in the system
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 14 September, 2013, http://www.business-standard.com/article/economy-policy/clinical-trials-expert-panel-s-views-differ-from-formula-under-study-113091400575_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 22660,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 22510
$metaTitle = &#039;LATEST NEWS UPDATES | Clinical trials: Expert panel&amp;#039;s views differ from formula under study-Sushmi Dey&#039;
$metaKeywords = &#039;Clinical Trials,Health,Law and Justice,Human Rights,medicines&#039;
$metaDesc = &#039;
-The Business Standard



Confusion over clinical trial compensation norms


Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Confusion over clinical trial compensation norms&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government&#039;s department of health and family welfare, work in the industry&#039;s favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&amp;quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &amp;quot;If they are not given compensation, their family members may not like to enrol them.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&amp;quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the formula under the health ministry&#039;s consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &amp;quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&amp;quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &amp;quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&amp;quot; the report said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;LATERAL SHIFT&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Key suggestions of the Ranjit Roy Chaudhary panel&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Audio-visual recording of the informed consent process be undertaken and the documentation preserved&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Compensation need not be paid for injury or death due to totally-proven unrelated causes&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;* IT be used at all steps of a clinical trial to ensure total transparency in the system&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Clinical trials: Expert panel&#039;s views differ from formula under study-Sushmi Dey | Im4change.org</title>
    <meta name="description" content="
-The Business Standard



Confusion over clinical trial compensation norms


Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Clinical trials: Expert panel&#039;s views differ from formula under study-Sushmi Dey</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Business Standard</div><p align="justify"><br /><em>Confusion over clinical trial compensation norms</em></p><p align="justify">Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.</p><p align="justify">The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.</p><p align="justify">This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.</p><p align="justify">The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government's department of health and family welfare, work in the industry's favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.</p><p align="justify">&quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &quot;If they are not given compensation, their family members may not like to enrol them.&quot;</p><p align="justify">However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.</p><p align="justify">&quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).</p><p align="justify">According to the formula under the health ministry's consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.</p><p align="justify">The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.</p><p align="justify">Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&quot; the report said.</p><p align="justify"><strong>LATERAL SHIFT</strong></p><p align="justify">Key suggestions of the Ranjit Roy Chaudhary panel</p><p align="justify">* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees</p><p align="justify">* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee</p><p align="justify">* Audio-visual recording of the informed consent process be undertaken and the documentation preserved</p><p align="justify">* Compensation need not be paid for injury or death due to totally-proven unrelated causes</p><p align="justify">* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs</p><p align="justify">* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation</p><p align="justify">* IT be used at all steps of a clinical trial to ensure total transparency in the system</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 22510,
		'title' => 'Clinical trials: Expert panel's views differ from formula under study-Sushmi Dey',
		'subheading' => '',
		'description' => '<div align="justify">
-The Business Standard
</div>
<p align="justify">
<br />
<em>Confusion over clinical trial compensation norms</em>
</p>
<p align="justify">
Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.
</p>
<p align="justify">
The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.
</p>
<p align="justify">
This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.
</p>
<p align="justify">
The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government's department of health and family welfare, work in the industry's favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.
</p>
<p align="justify">
&quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &quot;If they are not given compensation, their family members may not like to enrol them.&quot;
</p>
<p align="justify">
However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.
</p>
<p align="justify">
&quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).
</p>
<p align="justify">
According to the formula under the health ministry's consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.
</p>
<p align="justify">
The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.
</p>
<p align="justify">
Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&quot; the report said.
</p>
<p align="justify">
<strong>LATERAL SHIFT</strong>
</p>
<p align="justify">
Key suggestions of the Ranjit Roy Chaudhary panel
</p>
<p align="justify">
* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees
</p>
<p align="justify">
* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee
</p>
<p align="justify">
* Audio-visual recording of the informed consent process be undertaken and the documentation preserved
</p>
<p align="justify">
* Compensation need not be paid for injury or death due to totally-proven unrelated causes
</p>
<p align="justify">
* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs
</p>
<p align="justify">
* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation
</p>
<p align="justify">
* IT be used at all steps of a clinical trial to ensure total transparency in the system
</p>',
		'credit_writer' => 'The Business Standard, 14 September, 2013, http://www.business-standard.com/article/economy-policy/clinical-trials-expert-panel-s-views-differ-from-formula-under-study-113091400575_1.html',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 22660,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 22510,
	'metaTitle' => 'LATEST NEWS UPDATES | Clinical trials: Expert panel&#039;s views differ from formula under study-Sushmi Dey',
	'metaKeywords' => 'Clinical Trials,Health,Law and Justice,Human Rights,medicines',
	'metaDesc' => '
-The Business Standard



Confusion over clinical trial compensation norms


Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the...',
	'disp' => '<div align="justify">-The Business Standard</div><p align="justify"><br /><em>Confusion over clinical trial compensation norms</em></p><p align="justify">Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.</p><p align="justify">The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.</p><p align="justify">This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.</p><p align="justify">The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government's department of health and family welfare, work in the industry's favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.</p><p align="justify">&quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &quot;If they are not given compensation, their family members may not like to enrol them.&quot;</p><p align="justify">However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.</p><p align="justify">&quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).</p><p align="justify">According to the formula under the health ministry's consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.</p><p align="justify">The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.</p><p align="justify">Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&quot; the report said.</p><p align="justify"><strong>LATERAL SHIFT</strong></p><p align="justify">Key suggestions of the Ranjit Roy Chaudhary panel</p><p align="justify">* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees</p><p align="justify">* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee</p><p align="justify">* Audio-visual recording of the informed consent process be undertaken and the documentation preserved</p><p align="justify">* Compensation need not be paid for injury or death due to totally-proven unrelated causes</p><p align="justify">* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs</p><p align="justify">* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation</p><p align="justify">* IT be used at all steps of a clinical trial to ensure total transparency in the system</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 22510,
	'title' => 'Clinical trials: Expert panel&#039;s views differ from formula under study-Sushmi Dey',
	'subheading' => '',
	'description' => '<div align="justify">
-The Business Standard
</div>
<p align="justify">
<br />
<em>Confusion over clinical trial compensation norms</em>
</p>
<p align="justify">
Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.
</p>
<p align="justify">
The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.
</p>
<p align="justify">
This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.
</p>
<p align="justify">
The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government's department of health and family welfare, work in the industry's favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.
</p>
<p align="justify">
&quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &quot;If they are not given compensation, their family members may not like to enrol them.&quot;
</p>
<p align="justify">
However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.
</p>
<p align="justify">
&quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).
</p>
<p align="justify">
According to the formula under the health ministry's consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.
</p>
<p align="justify">
The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.
</p>
<p align="justify">
Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&quot; the report said.
</p>
<p align="justify">
<strong>LATERAL SHIFT</strong>
</p>
<p align="justify">
Key suggestions of the Ranjit Roy Chaudhary panel
</p>
<p align="justify">
* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees
</p>
<p align="justify">
* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee
</p>
<p align="justify">
* Audio-visual recording of the informed consent process be undertaken and the documentation preserved
</p>
<p align="justify">
* Compensation need not be paid for injury or death due to totally-proven unrelated causes
</p>
<p align="justify">
* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs
</p>
<p align="justify">
* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation
</p>
<p align="justify">
* IT be used at all steps of a clinical trial to ensure total transparency in the system
</p>',
	'credit_writer' => 'The Business Standard, 14 September, 2013, http://www.business-standard.com/article/economy-policy/clinical-trials-expert-panel-s-views-differ-from-formula-under-study-113091400575_1.html',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'clinical-trials-expert-panel039s-views-differ-from-formula-under-study-sushmi-dey-22660',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 22660,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 22510
$metaTitle = 'LATEST NEWS UPDATES | Clinical trials: Expert panel&#039;s views differ from formula under study-Sushmi Dey'
$metaKeywords = 'Clinical Trials,Health,Law and Justice,Human Rights,medicines'
$metaDesc = '
-The Business Standard



Confusion over clinical trial compensation norms


Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the...'
$disp = '<div align="justify">-The Business Standard</div><p align="justify"><br /><em>Confusion over clinical trial compensation norms</em></p><p align="justify">Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration.</p><p align="justify">The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol.</p><p align="justify">This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula.</p><p align="justify">The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government's department of health and family welfare, work in the industry's favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it.</p><p align="justify">&quot;Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given,&quot; said a health activist with the Swasthya Adhikar Manch. The activist added: &quot;If they are not given compensation, their family members may not like to enrol them.&quot;</p><p align="justify">However, the industry feels it is important for the government to recognise the nature of death while determining the compensation.</p><p align="justify">&quot;The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials,&quot; said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs).</p><p align="justify">According to the formula under the health ministry's consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given.</p><p align="justify">The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. &quot;The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations,&quot; the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials.</p><p align="justify">Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. &quot;The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation,&quot; the report said.</p><p align="justify"><strong>LATERAL SHIFT</strong></p><p align="justify">Key suggestions of the Ranjit Roy Chaudhary panel</p><p align="justify">* A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees</p><p align="justify">* The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee</p><p align="justify">* Audio-visual recording of the informed consent process be undertaken and the documentation preserved</p><p align="justify">* Compensation need not be paid for injury or death due to totally-proven unrelated causes</p><p align="justify">* No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs</p><p align="justify">* Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation</p><p align="justify">* IT be used at all steps of a clinical trial to ensure total transparency in the system</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Clinical trials: Expert panel's views differ from formula under study-Sushmi Dey

-The Business Standard Confusion over clinical trial compensation norms Even as the health ministry is evaluating a formula to compensate victims of clinical trials, an expert committee, headed by Ranjit Roy Chaudhury, has recommended some stringent measures that appear contrary to the formula under consideration. The committee, set up by the ministry to formulate policy and guidelines for clinical trials, has suggested that no compensation be given for therapeutic inefficiency during clinical trials or if it is proved the cause of death or injury is unrelated. Besides, the panel has recommended compensation not be given to terminally-ill patients, such as those suffering from cancer, if the primary end-point is death, according to the clinical trial protocol. This is in clear variance with the formula being considered by the ministry which suggests a fixed compensation of Rs 2 lakh for patients whose expected mortality is 90 per cent or more within 30 days. This is the minimum compensation being considered under the formula. The recommendations of the panel, headed by Roy Chaudhury, the national professor of pharmacology and advisor in the Delhi government's department of health and family welfare, work in the industry's favour. But health activists say it will not only hurt victims but also discourage many terminally-ill patients from enrolling for trials, as they would not see any benefit coming out of it. "Terminally-ill patients usually enrol for trials related to very complicated diseases, mainly cancer. In such cases, many untested drugs are often given," said a health activist with the Swasthya Adhikar Manch. The activist added: "If they are not given compensation, their family members may not like to enrol them." However, the industry feels it is important for the government to recognise the nature of death while determining the compensation. "The statistics of death are so vague, one cannot pinpoint whether it is due to clinical trials or illness. For example, if one is testing a cancer drug, cancer drugs, except in few cases, are used to just prolong the life by a few years or months. So, one considers those deaths as being due to clinical trials," said Shivprakash Rathnam, managing director of Ahmedabad-based Synchron Research Services, one of first clinical research organisations (CROs). According to the formula under the health ministry's consideration, compensation in other routine trial cases might vary from a minimum of Rs 4 lakh to a maximum of Rs 73,60,000, depending on the age of the deceased and the risk factor. However, in the case of patients whose expected mortality is 90 per cent or more within 30 days, a fixed amount of Rs 2 lakh could be given. The Roy Chaudhury committee has also recommended a single-window clearance for clinical trials. "The 12 drug advisory committees functioning at present will be replaced by one board-expertise-based technical review committee to ensure speedy clearance of applications without compromising on quality of data and rules and regulations," the committee said in its report, given to the Drugs Controller General of India (DCGI). The panel was set up in February this year and was also mandated to formulate rules for approval of new drugs and banning of drugs in the country, apart from looking into clinical trials. Another significant recommendation made by it includes creation of a fund by levying cess to be be used for compensation of clinical-trial victims. "The Government of India, state governments and institutions should create a fund to encourage academic and clinical research (non-pharmaceutical company-related) in institutions. The fund may be raised by imposing a cess, if needed. This fund will be available to the institution for paying compensation," the report said. LATERAL SHIFT Key suggestions of the Ranjit Roy Chaudhary panel * A central council be set up to oversee accreditation of institutes, clinical investigators and ethics committees * The 12 drug advisory panels functioning at present be replaced by an expertise-based technical review committee * Audio-visual recording of the informed consent process be undertaken and the documentation preserved * Compensation need not be paid for injury or death due to totally-proven unrelated causes * No compensation for therapeutic inefficiency, since the purpose of clinical trials is to determine efficacy and safety of drugs * Creation of fund to encourage academic and clinical research; could be raised by imposing a cess and made available to institutions for paying compensation * IT be used at all steps of a clinical trial to ensure total transparency in the system